Skip to main navigation Skip to search Skip to main content

Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use

  • Lawrence Mbuagbaw*
  • , Cristian Garcia
  • , Bluma Brenner
  • , Diego Cecchini
  • , Mohamed Chakroun
  • , Pascal Djiadeu
  • , Africa Holguin
  • , Orna Mor
  • , Neil Parkin
  • , Maria M. Santoro
  • , Santiago Ávila-Ríos
  • , Joseph Fokam
  • , Andrew Phillips
  • , Robert W. Shafer
  • , Michael R. Jordan
  • *Corresponding author for this work
  • Department of Health Research Methods
  • McMaster University
  • Department of Anesthesia
  • Division of Rheumatology
  • Biostatistics Unit
  • Centre for Development of Best Practices in Health
  • Central Hospital of Yaoundé
  • Department of Global Health
  • Stellenbosch University
  • Jewish General Hospital
  • McGill University
  • Department of Medicine
  • Hospital General de Agudos Dr. Cosme Argerich
  • Helios Salud
  • Infectious Diseases Department
  • Fatouma Bourguiba University Hospital
  • Yale University
  • University of Toronto
  • HIV-1 Molecular Epidemiology Laboratory
  • Hospital Ramon y Cajal
  • Ministry of Health, Israel
  • Data First Consulting, Inc.
  • Department of Experimental Medicine
  • University of Rome Tor Vergata
  • Instituto Nacional de Enfermedades Respiratorias
  • Centro de Investigaciones en Enfermedades Infecciosas
  • Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management
  • Faculty of Health Science
  • University of Buea
  • Ministère de la santé publique de Cameroun
  • University College London
  • Stanford University
  • Div. of Geographic Medicine and Infectious Diseases
  • Tufts Medical Center
  • Department of Public Health and Community Medicine
  • Tufts University
  • Tufts Center for Integrated Management of Antimicrobial Resistance

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

HIV drug resistance (HIVDR) is a major challenge to the effectiveness of antiretroviral therapy. Global efforts in addressing HIVDR require clear, transparent, and replicable reporting in HIVDR studies. We describe the rationale and recommended use of a checklist that should be included in reports of HIVDR incidence and prevalence. After preliminary consultations with experts on HIVDR and establishing the need for guidance on HIVDR reporting, we used a sequential, explanatory, mixed methods approach to create the checklist; together with the accompanying articles, the checklist was reviewed by the authors and validated externally. The checklist for studies on HIVDR prevalence or incidence (CEDRIC-HIV) includes 15 recommended items that would enhance transparency and facilitate interpretation, comparability, and replicability of HIVDR studies. CEDRIC-HIV will help authors of HIVDR studies prepare research reports and assist reviewers and editors in assessments of completeness of reporting. The checklist will also facilitate statistical pooling and interpretation of HIVDR data.

Original languageEnglish
Pages (from-to)e684-e689
JournalThe Lancet HIV
Volume10
Issue number10
DOIs
StatePublished - Oct 2023

Funding

Funders
Canadian HIV Trials Network Community Advisory Committee
Canadian Institutes of Health Research

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use'. Together they form a unique fingerprint.

    Cite this